VEGFA and age-related macular degeneration: presented the first ophthalmic drop for treating AMD via autophagy of aggregated protein and amyloid beta deposition.[32] The study also exemplified the first formulation to include (3β, 25R)‐spirost‐5‐en‐3‐ol (Dio), a natural, amphiphilic molecule capable of down‐regulating VEGF expression and inhibiting amyloid‐beta deposition.